Target intelligence / Profile preview

Streptococcus pneumoniae serotype 6A capsular polysaccharide (Pn6A PS)

Target
Pn6A PS
Molecular classification
Polysaccharide, Bacterial antigen
01

Overview

Streptococcus pneumoniae serotype 6A capsular polysaccharide is a complex carbohydrate polymer that forms the outermost layer of the 6A serotype of the pneumococcus bacterium. This polysaccharide is a critical virulence factor that enables the pathogen to evade the host's innate immune system by inhibiting opsonization and subsequent phagocytosis by leukocytes. It is composed of a repeating unit containing galactose, glucose, rhamnose, and ribitol phosphate, which distinguishes it immunologically from other pneumococcal serotypes. In clinical medicine, this polysaccharide serves as a primary antigen in various pneumococcal vaccines, including both polysaccharide and conjugate formulations. By introducing this antigen to the immune system, vaccines stimulate the production of specific antibodies that recognize and bind to the capsule of invading 6A bacteria. This binding facilitates the clearance of the pathogen through opsonophagocytosis, thereby preventing invasive diseases such as pneumonia, meningitis, and bacteremia. The inclusion of serotype 6A in vaccine formulations has significantly reduced the global burden of disease associated with this specific strain.

Other names
Pneumococcal serotype 6A polysaccharideCapsular polysaccharide 6ASpn6A CPStreptococcus pneumoniae type 6A antigen
02

Mechanism of action

Induction of humoral immunity through the production of serotype-specific opsonophagocytic antibodies that facilitate bacterial clearance by the host immune system.

03

Biological functions

Immune evasionVirulence factorProtection against phagocytosis
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaOtitis media
05

Safety considerations

Serotype replacement (emergence of non-vaccine serotypes)Injection site reactionsSystemic inflammatory responseHypersensitivity
06

Interacting drugs

Pneumococcal 13-valent conjugate vaccine (PCV13)

3 more in the full profile.

07

Biomarkers

Serotype-specific IgG antibody concentrationOpsonophagocytic activity (OPA) titer

Beyond the preview

Go deeper on Streptococcus pneumoniae serotype 6A capsular polysaccharide (Pn6A PS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae serotype 6A capsular polysaccharide (Pn6A PS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call